With the slowdown in world economic growth, the Age-Related Macular Degeneration Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Age-Related Macular Degeneration Drug market size to maintain the average annual growth rate of 0.0236676673112 from 5400.0 million $ in 2014 to 6070.0 million $ in 2018, Stratagem Market Insights analysts believe that in the next few years, Age-Related Macular Degeneration Drug market size will be further expanded, we expect that by 2023, The market size of the Age-Related Macular Degeneration Drug will reach 8100.0 million $.
Age-related macular degeneration (AMD) is an eye disorder that causes deterioration of the macula, a small central portion of the retina. It is the leading cause of severe, permanent vision loss in people over age 60. AMD is of two types: dry AMD and wet AMD. Dry AMD is a common form of macular degeneration. There is no treatment available for dry AMD. The less common type, wet AMD is characterized by abnormal blood vessels under the retina and can be managed through anti-vascular endothelial growth factor (anti-VEGF) injections.
A high incidence of AMD is expected to boost growth of the global age-related macular degeneration market over the forecast period. For instance, according to the BrightFocus Foundation, January 2019, around 11 million people in the U.S. suffered from macular degeneration, which is expected to double to nearly 22 million by 2050. Moreover, increasing the geriatric population is also expected to fuel the growth of the market. For instance, according to the World Health Organization, the geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015.
However, the high cost of treatment is expected to hinder the growth of the global age-related macular degeneration market. For instance, a single injection of anti-VEGF agents for the treatment of AMD such as ranibizumab costs around US$ 2000. Moreover, the growing use of off –label drugs and stringent regulatory scenarios is also expected to hamper the growth of the market.
The market is witnessing collaboration and partnership activities among major players. For instance, in September 2019, Boehringer Ingelheim entered into a co-development and license agreement with Inflammasome Therapeutics Inc. to develop three therapies for patients suffering from AMD, diabetic retinopathy, and diabetic macular edema.
Major players in the market are focused on product approval and launch to expand their product portfolio. For instance, in October 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for the Beovu (brolucizumab) injection for the treatment of wet AMD. Similarly, in August 2018, the U.S. FDA approved supplement Biologics License Application (sBLA) for Regeneron Pharmaceuticals, Inc.’s EYLEA injection for the treatment of wet AMD.
Key Takeaways:
- High incidence of AMD to augment the growth of the global age-related macular degeneration market over the forecast period
- High cost of treatment is expected to hinder the growth of the market
- Major players operating in the global age-related macular degeneration market include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, and Kanghong Pharma
This Report covers the manufacturers' data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume, and value, as well as price data.
Besides, the report also covers segment data, including type segment, industry segment, channel segment, etc. cover different segment market size, both volume, and value. Also cover different industries client's information, which is very important for the manufacturers. If you need more information,
Section 1: Definition
Section (2 3): Manufacturer Detail
╼ Regeneron Pharmaceuticals
╼ Bayer HealthCare
╼ Novartis
╼ Roche
╼ Kanghong Pharma
Section 4: Region Segmentation
╼ North America Country (United States, Canada)
╼ South America
╼ Asia Country (China, Japan, India, Korea)
╼ Europe Country (Germany, UK, France, Italy)
╼ Other Country (Middle East, Africa, GCC)
Section (5 6 7): Segmentation
Product Type Segmentation ⤍
╼ Lucentis
╼ Eylea
╼ Avastin
Industry Segmentation ⤍
╼ Hospitals
╼ Clinics
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2026)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
Request Discount 
Inquire Before Buy
